Agenus (NASDAQ:AGEN) Earns Sell Rating from Analysts at StockNews.com

Investment analysts at StockNews.com initiated coverage on shares of Agenus (NASDAQ:AGEN – Get Rating) in a research report issued to clients and investors on Thursday. The brokerage set a “sell” rating on the biotechnology company’s stock.

Other research analysts have also recently issued reports about the company. EF Hutton Acquisition Co. I reissued a “buy” rating and set a $8.30 price objective on shares of Agenus in a report on Wednesday. HC Wainwright reissued a “buy” rating and set a $8.00 price objective on shares of Agenus in a report on Tuesday, February 28th. One research analyst has rated the stock with a sell rating and three have assigned a buy rating to the stock. According to MarketBeat, Agenus presently has an average rating of “Moderate Buy” and a consensus price target of $7.10.

Agenus Price Performance

Shares of AGEN stock opened at $1.70 on Thursday. The stock has a market cap of $518.18 million, a P/E ratio of -2.15 and a beta of 1.50. Agenus has a one year low of $1.25 and a one year high of $3.37. The stock has a fifty day moving average price of $2.27 and a 200 day moving average price of $2.44.

Institutional Trading of Agenus

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Legal & General Group Plc increased its position in Agenus by 4.8% in the fourth quarter. Legal & General Group Plc now owns 109,787 shares of the biotechnology company’s stock worth $263,000 after purchasing an additional 5,011 shares during the period. Arizona State Retirement System grew its position in shares of Agenus by 8.5% during the 4th quarter. Arizona State Retirement System now owns 71,912 shares of the biotechnology company’s stock worth $173,000 after buying an additional 5,635 shares during the period. Amalgamated Bank grew its position in shares of Agenus by 15.6% during the 4th quarter. Amalgamated Bank now owns 51,958 shares of the biotechnology company’s stock worth $125,000 after buying an additional 7,005 shares during the period. Price T Rowe Associates Inc. MD grew its position in shares of Agenus by 4.0% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 190,889 shares of the biotechnology company’s stock worth $458,000 after buying an additional 7,390 shares during the period. Finally, California State Teachers Retirement System grew its position in shares of Agenus by 2.4% during the 3rd quarter. California State Teachers Retirement System now owns 321,557 shares of the biotechnology company’s stock worth $659,000 after buying an additional 7,663 shares during the period. 53.81% of the stock is currently owned by institutional investors and hedge funds.

About Agenus

(Get Rating)

Agenus, Inc is a clinical-stage immuno-oncology company, which engages in the development and commercialization of technologies to treat cancers and infectious diseases. Its product pipeline includes Balstilimab, Zalifrelimab, AGEN1181, AGEN1327, AGEN2373, AGENt-797 and AGEN1777. The company was founded by Garo H.